Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of JRA by the American College of Rheumatology (ACR) criteria.~* Disease course must be polyarticular with disease duration long enough to have been given an adequate trial of non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose methotrexate at a dose of at least 10 mg/m²/week~* Continuing active disease, defined as ≥ 5 swollen joints and ≥ 3 joints with limitation of motion accompanied by pain, tenderness or warmth.~* Disease refractory to methotrexate or intolerant of methotrexate.~* Have not received disease-modifying anti-rheumatic drugs (DMARDs) within 28 days prior to enrollment.~* Have not received methotrexate within 14 days prior to dosing of study drug.~Exclusion Criteria:~* Pregnant or nursing female~* Functional class IV by ACR criteria~* Unable to meet concomitant medication restrictions~* Intraarticular corticosteroid injection within 4 weeks prior to enrollment~* Clinically significant deviations from normal, defined as:~  * thrombocytopenia; platelet count \< 100,000/cmm~ * leukopenia; total white cell count \< 4000 cells/cmm~ * neutropenia; neutrophils \< 1000 cells/cmm~ * hepatic transaminase levels \> two times the upper limit of normal (ULN)~ * serum bilirubin \> 2 times ULN~ * creatinine clearance \< 90 mL/min/1.73 m² body surface area (BSA) and/or a glomerular filtration rate (GFR) \< 90 mL/min/1.73 m² BSA.~ * known human immunodeficiency virus (HIV), hepatitis B surface antigen positivity, or hepatitis C positivity.~ * anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies or anti-cardiolipin antibodies present.~* Previously received antibody to TNF, antibody to cluster of differentiation (CD)4, or diphtheria interleukin (IL)-2-fusion protein (DAB-IL-2)~* Participated in a study of an investigational drug or biologic requiring informed consent within 3 months prior to study entry.~* Any concurrent medical condition which would, in the investigator's opinion, compromise the patient's ability to tolerate the study drug or make the patient unable to cooperate with the protocol.~* History of or current psychiatric illness that would interfere with ability to comply with protocol requirements or informed consent.~* History or drug or alcohol abuse that would interfere with ability to comply with protocol requirements

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept/Placebo (Type: PLACEBO_COMPARATOR): Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
- Etanercept/Etanercept (Type: EXPERIMENTAL): Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.

Based on this trial design, predict the completion outcome and termination type (if applicable).